COMPARE · Data as of August 21, 2026
HRMY vs INSM
Verdict: Side-by-side breakdown using the Bull Rankings model. HRMY scored 88.7, INSM scored 38.6 — HRMY leads.
Compare another set
HRMY
Harmony Biosciences Holdings, Inc.
88.7
$38.15 · $2.2B
fundamentals as of
Score gap
50.1
HRMY leads
INSM
Insmed Incorporated
38.6
$125.77 · $27.5B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- Fastest growthINSM+185.8%
- Strongest balance sheetHRMY0.16
- Highest qualityHRMY80 / 100
- Largest discount to fair valueHRMY-75%
Side by side · every name on one set of axes
The model, pillar by pillar (0–100 each)
HRMY
stronger →← stronger
INSM
80
Qualityreturns · margins · balance sheet
11
91
Growthrevenue & earnings expansion
98
95
Valuevaluation vs sector peers
55
HRMY is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
HRMY
INSM
$355mC
FCF
-$808mF
+24.3%A-
Rev
+185.8%A
0.16B+
D/E
0.98C
12.3xA
P/E
—
0.44A
PEG
1.09B+
—
P/S
24.1xD
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
HRMY
INSM
75% below
Price vs fair valuelower is cheaper
—
~-18%/yr
Growth the price implies10-yr FCF · lower = less priced in
—
+206%
1-yr DCF upside
—
+303%
5-yr DCF upside
—
+506%
10-yr DCF upside
—
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
HRMY
Why this score
- Durable high returns
INSM
Why this score
- Diluting shareholders
The companies
HRMYHarmony Biosciences Holdings, Inc.
Why now
Biotechnology · market cap $2.2b. 7% off the 52-week high of $40.87. Revenue growing +24%, comfortably above the S&P median. PEG 0.44 — paying under fair value for the growth rate. 10 sell-side analysts rate this a Buy with a mean 1-yr target of $46.10 (implying +21% upside).
Moat
Net margin 19% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 18% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 196% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
INSMInsmed Incorporated
Why now
Biotechnology · market cap $27.5b. Down 41% from 52-week high of $212.75 — deep drawdown territory. Revenue growing +186% — in hypergrowth territory. 22 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $200.05 (implying +59% upside).
Moat
Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Free cash flow is negative (-$808m) — capital raises or debt issuance likely required; dilution / leverage risk. Currently unprofitable (margin -76.9%) — path to GAAP profitability is the core thesis risk. Down 41% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where HRMY and INSM diverge
On the headline score the gap is 50.1 points in favor of HRMY. They get there differently, though — each leads on a different pillar, so the better pick depends on which you weight.
- QualityHRMY 79.9 · INSM 10.6HRMY +69.3
- ValueHRMY 95.4 · INSM 55.5HRMY +39.9
- GrowthHRMY 91.5 · INSM 97.8INSM +6.3
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.